Búsqueda | Portal de Búsqueda de la BVS España

1.

Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches.

Cortiula, F; Reymen, B; Peters, S; Van Mol, P; Wauters, E; Vansteenkiste, J; De Ruysscher, D; Hendriks, L E L.

Ann Oncol; 33(9): 893-908, 2022 09.

Artículo en Inglés | MEDLINE | ID: mdl-35777706

2.

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.

Passaro, A; Leighl, N; Blackhall, F; Popat, S; Kerr, K; Ahn, M J; Arcila, M E; Arrieta, O; Planchard, D; de Marinis, F; Dingemans, A M; Dziadziuszko, R; Faivre-Finn, C; Feldman, J; Felip, E; Curigliano, G; Herbst, R; Jänne, P A; John, T; Mitsudomi, T; Mok, T; Normanno, N; Paz-Ares, L; Ramalingam, S; Sequist, L; Vansteenkiste, J; Wistuba, I I; Wolf, J; Wu, Y L; Yang, S R; Yang, J C H; Yatabe, Y; Pentheroudakis, G; Peters, S.

Ann Oncol; 33(5): 466-487, 2022 05.

Artículo en Inglés | MEDLINE | ID: mdl-35176458

3.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.

Park, K; Vansteenkiste, J; Lee, K H; Pentheroudakis, G; Zhou, C; Prabhash, K; Seto, T; Voon, P J; Tan, D S W; Yang, J C H; Wang, J; Babu, K Govind; Nakayama, Y; Alip, A; Chua, K L M; Cheng, J C-H; Senan, S; Ahn, Y C; Kim, T-Y; Ahn, H K; Peters, S; Yoshino, T; Douillard, J-Y.

Ann Oncol; 31(2): 191-201, 2020 02.

Artículo en Inglés | MEDLINE | ID: mdl-31959336

4.

Current status of immune checkpoint inhibition in early-stage NSCLC.

Vansteenkiste, J; Wauters, E; Reymen, B; Ackermann, C J; Peters, S; De Ruysscher, D.

Ann Oncol; 30(8): 1244-1253, 2019 08 01.

Artículo en Inglés | MEDLINE | ID: mdl-31143921

5.

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.

Bonomi, P D; Gandara, D; Hirsch, F R; Kerr, K M; Obasaju, C; Paz-Ares, L; Bellomo, C; Bradley, J D; Bunn, P A; Culligan, M; Jett, J R; Kim, E S; Langer, C J; Natale, R B; Novello, S; Pérol, M; Ramalingam, S S; Reck, M; Reynolds, C H; Smit, E F; Socinski, M A; Spigel, D R; Vansteenkiste, J F; Wakelee, H; Thatcher, N.

Ann Oncol; 29(8): 1701-1709, 2018 08 01.

Artículo en Inglés | MEDLINE | ID: mdl-29905778

6.

Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer.

Decoster, L; Kenis, C; Schallier, D; Vansteenkiste, J; Nackaerts, K; Vanacker, L; Vandewalle, N; Flamaing, J; Lobelle, J P; Milisen, K; De Grève, J; Wildiers, H.

Lung; 195(5): 619-626, 2017 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-28634893

7.

Acquired resistance in NSCLC: the journey from clinical definition to molecular understanding.

Wauters, E; Vansteenkiste, J.

Ann Oncol; 32(12): 1463-1465, 2021 12.

Artículo en Inglés | MEDLINE | ID: mdl-34610278

8.

Metabolic phenotyping of human blood plasma: a powerful tool to discriminate between cancer types?

Louis, E; Adriaensens, P; Guedens, W; Vanhove, K; Vandeurzen, K; Darquennes, K; Vansteenkiste, J; Dooms, C; de Jonge, E; Thomeer, M; Mesotten, L.

Ann Oncol; 27(1): 178-84, 2016 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-26487580

9.

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up^â.

Dingemans, A-M C; Früh, M; Ardizzoni, A; Besse, B; Faivre-Finn, C; Hendriks, L E; Lantuejoul, S; Peters, S; Reguart, N; Rudin, C M; De Ruysscher, D; Van Schil, P E; Vansteenkiste, J; Reck, M.

Ann Oncol; 32(7): 839-853, 2021 07.

Artículo en Inglés | MEDLINE | ID: mdl-33864941

10.

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.

Jänne, P A; Smith, I; McWalter, G; Mann, H; Dougherty, B; Walker, J; Orr, M C M; Hodgson, D R; Shaw, A T; Pereira, J R; Jeannin, G; Vansteenkiste, J; Barrios, C H; Franke, F A; Crinò, L; Smith, P.

Br J Cancer; 113(2): 199-203, 2015 Jul 14.

Artículo en Inglés | MEDLINE | ID: mdl-26125448

11.

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).

Vansteenkiste, J; Barlesi, F; Waller, C F; Bennouna, J; Gridelli, C; Goekkurt, E; Verhoeven, D; Szczesna, A; Feurer, M; Milanowski, J; Germonpre, P; Lena, H; Atanackovic, D; Krzakowski, M; Hicking, C; Straub, J; Picard, M; Schuette, W; O'Byrne, K.

Ann Oncol; 26(8): 1734-40, 2015 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-25939894

12.

2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.

Vansteenkiste, J; Crinò, L; Dooms, C; Douillard, J Y; Faivre-Finn, C; Lim, E; Rocco, G; Senan, S; Van Schil, P; Veronesi, G; Stahel, R; Peters, S; Felip, E.

Ann Oncol; 25(8): 1462-74, 2014 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-24562446

13.

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration.

Mountzios, G; Remon, J; Novello, S; Blais, N; Califano, R; Cufer, T; Dingemans, A M; Liu, S V; Peled, N; Pennell, N A; Reck, M; Rolfo, C; Tan, D; Vansteenkiste, J; West, H; Besse, B.

Ann Oncol; 30(11): 1686-1688, 2019 11 01.

Artículo en Inglés | MEDLINE | ID: mdl-31504132

14.

Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years.

Vansteenkiste, J; Wauters, E.

Ann Oncol; 29(suppl_1): i1-i2, 2018 01 01.

Artículo en Inglés | MEDLINE | ID: mdl-29462258

15.

Will liquid biopsies become our fluid transition to personalized immunotherapy?

Wauters, E; Vansteenkiste, J.

Ann Oncol; 29(1): 11-13, 2018 01 01.

Artículo en Inglés | MEDLINE | ID: mdl-29165546

16.

Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLC.

Vanden Bempt, I; Wauters, E; Vansteenkiste, J.

Ann Oncol; 29(4): 789-791, 2018 04 01.

Artículo en Inglés | MEDLINE | ID: mdl-29432543

17.

Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.

Kreuter, M; Vansteenkiste, J; Fischer, J R; Eberhardt, W; Zabeck, H; Kollmeier, J; Serke, M; Frickhofen, N; Reck, M; Engel-Riedel, W; Neumann, S; Thomeer, M; Schumann, C; De Leyn, P; Graeter, T; Stamatis, G; Zuna, I; Griesinger, F; Thomas, M.

Ann Oncol; 24(4): 986-92, 2013 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-23161898

18.

Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development.

Decoster, L; Wauters, I; Vansteenkiste, J F.

Ann Oncol; 23(6): 1387-93, 2012 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-22156658

19.

Screening and early detection of lung cancer.

Vansteenkiste, J; Dooms, C; Mascaux, C; Nackaerts, K.

Ann Oncol; 23 Suppl 10: x320-7, 2012 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-22987984

20.

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Postmus, P E; Kerr, K M; Oudkerk, M; Senan, S; Waller, D A; Vansteenkiste, J; Escriu, C; Peters, S.

Ann Oncol; 28(suppl_4): iv1-iv21, 2017 07 01.

Artículo en Inglés | MEDLINE | ID: mdl-28881918

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar: